Humoral Immune Memory to Hepatitis B Vaccine After Primary Vaccination of Children and Adolescents in Assiut, Egypt

Overview

Journal Oman Med J

Specialty General Medicine

Date 2020 Oct 21

PMID 33083033

Citations 1

Authors

Iman I Salama

Samia M Sami

Safaa M Elserougy

Hanaa M Emam

Somaia I Salama

Hazem M Elhariri

Samia A Hemeda

Amal I Hassanain

Aida M Abdel Mohsen

Walaa A Fouad

Lobna A El Etreby

Zeinab N Said

Affiliations

Soon will be listed here.

Abstract

Objectives: We sought to assess the prevalence of hepatitis B virus (HBV) seroprotection among vaccinated children in the Assiut governorate, Egypt, and assess a booster dose immune memory response among non-seroprotected children.

Methods: Using a multistage cluster sample, 566 children were recruited from three clusters: one urban and two rural. Children were aged from nine months to 16 years old. All participants received the full three doses of the compulsory HBV vaccine during infancy. Serum hepatitis B surface antigen (HBsAg), total anti-hepatitis B core (anti-HBc) antibodies, and quantitative detection of anti-HBs were measured using enzyme-linked immunosorbent assay. Repeatedly positive samples for HBsAg/anti-HBc were submitted for quantitative HBV DNA detection using real-time polymerase chain reaction. Non-seroprotective participants (anti-HBs < 10 IU/L) were given a booster dose of HBV vaccine. Two weeks later, a blood sample was taken from each child to assess an anamnestic response.

Results: The seroprotection rate was 53.2%, and only two children had HBV breakthrough infection (0.4%) with positive serum anti-HBc and HBV DNA. Age was the only significant predictor for non-seroprotection with an adjusted odds ratio (OR) of 3.2, 9.4, and 9.9 among children aged 5-10, 11-15, and > 15 years, respectively, compared to younger children ( < 0.001). About 85% of non-seroprotected children developed an anamnestic response after receiving the booster dose, and 84.3% of responders had a good response ( 100 IU/L). Undetectable pre-booster titer was found to be the only risk factor for non-response to booster with OR = 3.2 ( < 0.010). About 95.7% of children who were not responding to booster dose developed immune response after receiving the three doses of HBV vaccine.

Conclusions: Older age of children was the only significant predictor for HBV non-seroprotection. High anamnestic response rate signifies the presence of immune memory with long-term protection despite the waning of anti-HBs over time. However, some children with pre-booster undetectable anti-HBs titers may be unable to develop anamnestic response, and a second vaccination series might be necessary for HBV protection for these children.

Citing Articles

Current and novel modalities for management of chronic hepatitis B infection.

Ibrahim Salama I, Sami S, Salama S, Abdel-Latif G, Shaaban F, Fouad W World J Hepatol. 2023; 15(5):585-608.

PMID: 37305370 PMC: 10251278. DOI: 10.4254/wjh.v15.i5.585.

References

Saffar M, Rezai M . Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. Indian Pediatr. 2004; 41(12):1232-7. View

FitzSimons D, Hendrickx G, Vorsters A, Van Damme P . Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine. 2012; 31(4):584-90. DOI: 10.1016/j.vaccine.2012.10.101. View

Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A . Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine. 2009; 28(3):623-31. DOI: 10.1016/j.vaccine.2009.10.068. View

Nabil Ahmed Said Z, Abdelwahab K . Induced immunity against hepatitis B virus. World J Hepatol. 2015; 7(12):1660-70. PMC: 4483547. DOI: 10.4254/wjh.v7.i12.1660. View

Jafarzadeh A, Montazerifar S . Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2007; 18(4):4-9. View

Zanetti A, Van Damme P, Shouval D . The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008; 26(49):6266-73. DOI: 10.1016/j.vaccine.2008.09.056. View

Sadeghi A, Yahyapour Y, Poortahmasebi V, Shahmoradi S, Roggendorf M, Karimzadeh H . Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection. J Viral Hepat. 2015; 23(4):282-5. DOI: 10.1111/jvh.12490. View

El-Raziky M, El-Hawary M, Salama K, El-Hennawy A, Helmy H, Fahmy M . Patterns of hepatitis B infection in Egyptian children in the era of obligatory hepatitis B vaccination. Arab J Gastroenterol. 2012; 13(1):1-3. DOI: 10.1016/j.ajg.2012.02.003. View

Zanetti A, Parlato A, Romano L, Desole M, Ferrera G, Giurdanella F . Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy. Vaccine. 2012; 30(39):5770-5. DOI: 10.1016/j.vaccine.2012.06.078. View

10.

Su F, Cheng S, Li C, Chen J, Hsiao C, Chien C . Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007; 25(47):8085-90. DOI: 10.1016/j.vaccine.2007.09.013. View

11.

Lu C, Ni Y, Chiang B, Chen P, Chang M, Chang L . Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008; 197(10):1419-26. DOI: 10.1086/587695. View

12.

Saffar H, Ajami A, Saffar M, Shojaei J, Sotudeh-Anvari M, Shams-Esfandabad K . Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in iran. Hepat Mon. 2014; 14(5):e17263. PMC: 4013494. DOI: 10.5812/hepatmon.17263. View

13.

Wang Q, Klenerman P, Semmo N . Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017; 2(2):123-134. DOI: 10.1016/S2468-1253(16)30076-0. View

14.

Zanetti A, Desole M, Romano L, DAlessandro A, Conversano M, Ferrera G . Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy. Vaccine. 2017; 35(32):4034-4040. DOI: 10.1016/j.vaccine.2017.05.047. View

15.

Salama I, Sami S, Nabil Ahmed Said Z, El-Sayed M, El Etreby L, Rabah T . Effectiveness of hepatitis B virus vaccination program in Egypt: Multicenter national project. World J Hepatol. 2015; 7(22):2418-26. PMC: 4598613. DOI: 10.4254/wjh.v7.i22.2418. View

16.

Baylis S, Heath A, Chudy M, Pisani G, Klotz A, Kerby S . An international collaborative study to establish the 2nd World Health Organization International Standard for hepatitis B virus DNA nucleic acid amplification technology-based assays. Vox Sang. 2008; 94(4):358-62. DOI: 10.1111/j.1423-0410.2008.01023.x. View

17.

Xiao J, Zhang J, Wu C, Shao X, Peng G, Peng Z . Impact of hepatitis B vaccination among children in Guangdong Province, China. Int J Infect Dis. 2012; 16(9):e692-6. DOI: 10.1016/j.ijid.2012.05.1027. View

18.

Lu S, Ren J, Li Q, Jiang Z, Chen Y, Xu K . Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization. Hum Vaccin Immunother. 2016; 13(4):903-908. PMC: 5404365. DOI: 10.1080/21645515.2016.1260794. View

19.

Hammitt L, Hennessy T, Fiore A, Zanis C, Hummel K, Dunaway E . Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007; 25(39-40):6958-64. DOI: 10.1016/j.vaccine.2007.06.059. View

20.

Salama I, Sami S, Salama S, Rabah T, El Etreby L, Abdel Hamid A . Immune response to second vaccination series of hepatitis B virus among booster dose non-responders. Vaccine. 2016; 34(16):1904-8. DOI: 10.1016/j.vaccine.2016.02.050. View